Bristol Myers Updates Action Date for Subcutaneous Opdivo - ALX Oncology Holdings (NASDAQ:ALXO), Bristol-Myers Squibb (NYSE:BMY)

Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.

Related Keywords

, Bristol Myers , Bristol Myers Squibb , Oncology Holdings , Karuna Therapeutics Inc , Mirati Therapeutics , Karuna Therapeutics , Zacks Rank , Zacks Consensus Estimate ,